Characteristic adverse events and their incidence among patients participating in acute ischemic stroke trials

Stroke

Volumn 45, Issue 9, 2014, Pages 2677-2682

  Hesse, Kerrick ^a   Fulton, Rachael L ^a   Abdul Rahim, Azmil H ^a   Lees, Kennedy R ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

complications; prognosis; stroke

Indexed keywords

PLACEBO;

ACUTE DISEASE; AGED; CLINICAL TRIAL (TOPIC); COMORBIDITY; COMPLICATION; FEMALE; HUMAN; INCIDENCE; ISCHEMIA; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; RISK; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; STROKE; TREATMENT OUTCOME; VERY ELDERLY;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; CLINICAL TRIALS AS TOPIC; COMORBIDITY; FEMALE; HUMANS; INCIDENCE; ISCHEMIA; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; ROC CURVE; SEVERITY OF ILLNESS INDEX; STROKE; TREATMENT OUTCOME;

EID: 84906817593     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.114.005845     Document Type: Article

References (48)

1. Ali M, Atula S, Bath PMW, Grotta J, Hacke W, Lyden P, et al; VISTA Investigators. Stroke outcome in clinical trial patients deriving from different countries. Stroke. 2009;40:35-40.
2. Johnston KC, Li JY, Lyden PD, Hanson SK, Feasby TE, Adams RJ, et al. Medical and neurological complications of ischemic stroke: experience from the RANTTAS trial. RANTTAS Investigators. Stroke. 1998;29:447-453.
3. Aslanyan S, Weir CJ, Diener HC, Kaste M, Lees KR; GAIN International Steering Committee and Investigators. Pneumonia and urinary tract infection after acute ischaemic stroke: a tertiary analysis of the GAIN International trial. Eur J Neurol. 2004;11:49-53.
4. Food and Drug Administration. Guidance for clinical investigators, sponsors, and IRBs: adverse event reporting to IRBs-improving human subject protection [Internet]. Rockville, MD: Food and Drug Administration; January 2009. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm126572. pdf. Accessed October 1, 2013.
5. The National Archives. The medicines for human use (clinical trials) regulations 2004 [Internet]. United Kingdom: The National Archives; March 2004. http://www.legislation.gov.uk/uksi/2004/1031/regulation/32/made. Accessed October 1, 2013.
6. European Commission. Communication from the Commission-detailed guidance on the collection, verification and presentation of adverse event/reaction reports arising from clinical trials on medicinal products for human use ('CT-3') [Internet]. European Commission; June 2011. http://ec.europa.eu/health/ files/eudralex/vol-10/2011-c172-01/2011-c172-01-en.pdf. Accessed October 1, 2013.
7. Ali M, Sacco RL, Lees KR. Primary end-point times, functional outcome, and adverse event profile after acute ischemic stroke. Int J Stroke. 2009;4:432-42.
8. Vernino S, Brown RD Jr, Sejvar JJ, Sicks JD, Petty GW, O'Fallon WM. Cause-specific mortality after first cerebral infarction: a populationbased study. Stroke. 2003;34:1828-1832.
9. Roth EJ, Lovell L, Harvey RL, Heinemann AW, Semik P, Diaz S. Incidence of and risk factors for medical complications during stroke rehabilitation. Stroke. 2001;32:523-529.
10. Teal P, Davis S, Hacke W, Kaste M, Lyden PD, Fierus M; Modified Randomized Exposure Controlled Trial Study Investigators; Bayer HealthCare AG. A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, tolerability, and pharmacokinetic/pharmacodynamic effects of a targeted exposure of intravenous repinotan in patients with acute ischemic stroke: modified Randomized Exposure Controlled Trial (mRECT). Stroke. 2009;40:3518-3525.
11. Levy DE, del Zoppo GJ, Demaerschalk BM, Demchuk AM, Diener HC, Howard G, et al. Ancrod in acute ischemic stroke: results of 500 subjects beginning treatment within 6 hours of stroke onset in the ancrod stroke program. Stroke. 2009;40:3796-3803.
12. Diener HC, Schneider D, Lampl Y, Bornstein NM, Kozak A, Rosenberg G. DP-b99, a membrane-activated metal ion chelator, as neuroprotective therapy in ischemic stroke. Stroke. 2008;39:1774-1778.
13. Adams HP, Hacke W, Oemar B, Davalos A, Cook RA, Trouillas P, et al. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of a randomized phase 2 trial. Stroke. 2005;36:880-890.
14. Lyden P, Jacoby M, Schim J, Albers G, Mazzeo P, Ashwood T, et al. The Clomethiazole Acute Stroke Study in tissue-type plasminogen activatortreated stroke (CLASS-T): final results. Neurology. 2001;57:1199-1205.
15. Diener HC, Cortens M, Ford G, Grotta J, Hacke W, Kaste M, et al. Lubeluzole in acute ischemic stroke treatment: a double-blind study with an 8-hour inclusion window comparing a 10-mg daily dose of lubeluzole with placebo. Stroke. 2000;31:2543-2551.
16. Albers GW, Goldstein LB, Hall D, Lesko LM; Aptiganel Acute Stroke Investigators. Aptiganel hydrochloride in acute ischemic stroke: a randomized controlled trial. JAMA. 2001;286:2673-2682.
17. Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener HC, et al; Stroke-Acute Ischemic NXY Treatment (SAINT I) Trial Investigators. NXY-059 for acute ischemic stroke. N Engl J Med. 2006;354:588-600.
18. Shuaib A, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, et al; SAINT II Trial Investigators. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med. 2007;357:562-571.
19. Bath PMW, Martin RH, Palesch Y, Cotton D, Yusuf S, Sacco R, et al; PRoFESS Study Group. Effect of telmisartan on functional outcome, recurrence, and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke. 2009;40:3541-3546.
20. Bath PMW, Cotton D, Martin RH, Palesch Y, Yusuf S, Sacco R, et al; PRoFESS Study Group. Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PRoFESS subgroup analysis. Stroke. 2010;41:732-738.
21. Schäbitz WR, Laage R, Vogt G, Koch W, Kollmar R, Schwab S, et al. AXIS: a trial of intravenous granulocyte colony-stimulating factor in acute ischemic stroke. Stroke. 2010;41:2545-2551.
22. Ehrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C, Wartenberg K, et al; EPO Stroke Trial Group. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke. 2009;40:e647-e656.
23. Clark WM, Wechsler LR, Sabounjian LA, Schwiderski UE; Citicoline Stroke Study Group. A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology. 2001;57:1595-1602.
24. Horn J, de Haan RJ, Vermeulen M, Limburg M. Very Early Nimodipine Use in Stroke (VENUS): a randomized, double-blind, placebo-controlled trial. Stroke. 2001;32:461-465.
25. Lees KR, Asplund K, Carolei A, Davis SM, Diener HC, Kaste M, et al. Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. GAIN International Investigators. Lancet. 2000;355:1949-1954.
26. Davis SM, Lees KR, Albers GW, Diener HC, Markabi S, Karlsson G, et al. Selfotel in acute ischemic stroke: possible neurotoxic effects of an NMDA antagonist. Stroke. 2000;31:347-354.
27. Clark WM, Raps EC, Tong DC, Kelly RE. Cervene (Nalmefene) in acute ischemic stroke: final results of a phase III efficacy study. The Cervene Stroke Study Investigators. Stroke. 2000;31:1234-1239.
28. Krams M, Lees KR, Hacke W, Grieve AP, Orgogozo JM, Ford GA; ASTIN Study Investigators. Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke. Stroke. 2003;34:2543-2548.
29. Elting JW, Sulter GA, Kaste M, Lees KR, Diener HC, Hommel M, et al. AMPA antagonist ZK200775 in patients with acute ischemic stroke: possible glial cell toxicity detected by monitoring of S-100B serum levels. Stroke. 2002;33:2813-2818.
30. Dippel DW, van Breda EJ, van Gemert HM, van der Worp HB, Meijer RJ, Kappelle LJ, et al. Effect of paracetamol (acetaminophen) on body temperature in acute ischemic stroke: a double-blind, randomized phase II clinical trial. Stroke. 2001;32:1607-1612.
31. Lees KR, Dyker AG, Sharma A, Ford GA, Ardron ME, Grosset DG. Tolerability of the low-affinity, use-dependent NMDA antagonist AR-R15896AR in stroke patients: a dose-ranging study. Stroke. 2001;32: 466-472.
32. Thijs VN, Peeters A, Vosko M, Aichner F, Schellinger PD, Schneider D, et al. Randomized, placebo-controlled, dose-ranging clinical trial of intravenous microplasmin in patients with acute ischemic stroke. Stroke. 2009;40:3789-3795.
33. Haley EC, Thompson JLP, Grotta JC, Lyden PD, Hemmen TG, Brown DL, et al. Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a Prematurely Terminated Randomized Clinical Trial. Stroke. 2010;41:707-711.
34. Adams HP Jr, Effron MB, Torner J, Dávalos A, Frayne J, Teal P, et al; AbESTT-II Investigators. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). Stroke. 2008;39:87-99.
35. Pancioli AM, Broderick J, Brott T, Tomsick T, Khoury J, Bean J, et al; CLEAR Trial Investigators. The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial. Stroke. 2008;39:3268-3276.
36. Diener HC, Ringelstein EB, von Kummer R, Landgraf H, Koppenhagen K, Harenberg J, et al; PROTECT Trial Group. Prophylaxis of thrombotic and embolic events in acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the PROTECT Trial. Stroke. 2006;37:139-144.
37. LaMonte MP, Nash ML, Wang DZ, Woolfenden AR, Schultz J, Hursting MJ, et al; ARGIS-1 Investigators. Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1): a randomized, placebo-controlled safety study. Stroke. 2004;35:1677-1682.
38. Albers GW, Clark WM, Madden KP, Hamilton SA. ATLANTIS Trial: results for patients treated within 3 hours of stroke onset. Stroke. 2002;33:493-496.
39. Diener HC, Ringelstein EB, von Kummer R, Langohr HD, Bewermeyer H, Landgraf H, et al. Treatment of acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the TOPAS trial. Therapy of Patients With Acute Stroke (TOPAS) Investigators. Stroke. 2001;32:22-29.
40. Clark WM, Albers GW, Madden KP, Hamilton S. The rtPA (alteplase) 0-to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators. Stroke. 2000;31:811-816.
41. Adams HP, Bogousslavsky J, Barnathan E, Brott T, Fisher M, Furlan AJ, et al. Abciximab in acute ischemic stroke: a randomized, double-blind, placebo-controlled, dose-escalation study. Stroke. 2000;31:601-609.
42. Albers GW, Goldstein LB, Hall D, Lesko LM; Aptiganel Acute Stroke Investigators. Aptiganel hydrochloride in acute ischemic stroke: a randomized controlled trial. JAMA. 2001;286:2673-2682.
43. Diener HC, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, et al; SAINT I and II Investigators. NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials. Stroke. 2008;39:1751-1758.
44. Muir SW, Harrow C, Dawson J, Lees KR, Weir CJ, Sattar N, et al. Allopurinol use yields potentially beneficial effects on inflammatory indices in those with recent ischemic stroke: a randomized, double-blind, placebo-controlled trial. Stroke. 2008;39:3303-3307.
45. Ali M, Bath P, Brady M, Davis S, Diener HC, Donnan G, et al; VISTA Steering Committees. Development, expansion, and use of a stroke clinical trials resource for novel exploratory analyses. Int J Stroke. 2012;7:133-138.
46. Longmore M, Wilkinson IB, Davidson EH, Foulkes A, Mafi AR. Oxford Handbook of Clinical Medicine. 8th ed. Oxford: Oxford University Press; 2010.
47. ICH. Introductory guide MedDRA version 16.1. ICH; September 2013. http://www.meddra.org/sites/default/files/guidance/file/intguide-16-1-english. pdf. Accessed October 1, 2013.
48. Fink JN, Frampton CM, Lyden P, Lees KR; Virtual International Stroke Trials Archive Investigators. Does hemispheric lateralization influence functional and cardiovascular outcomes after stroke?: an analysis of placebo-treated patients from prospective acute stroke trials. Stroke. 2008;39:3335-3340.